Wednesday, February 29, 2012
Human Genome Sciences Inc., of Rockville, Md., reported fourth-quarter 2011 revenues of $45.5 million, with $25.7 million coming from sales of lupus drug Benlysta (belimumab), in line with what the firm had pre-announced last month. Net loss for the quarter totaled $81 million, or 41 cents per share, narrower than the consensus estimates of a loss of 43 cents per share.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.